Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia
Open Access
- 8 September 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 12
Abstract
Dementia is a syndrome of acquired cognitive impairment that leads to a significant decline in a patient’s daily life, ability to learn, and the ability to communicate with others. Dementia occurs in many diseases, including Alzheimer’s disease (AD), dementia with Lewy bodies, frontotemporal dementia, and Parkinson’s disease dementia (PDD). Although the analysis of biomarkers in the cerebrospinal fluid (CSF) and peripheral blood physicochemical analysis can indicate neurological impairment, there are currently no sensitive biomarkers for early clinical diagnosis of dementia or for identifying the cause of dementia. Previous studies have suggested that circulating micro (mi)RNAs may be used as biomarkers for diagnosing neurological disorders. However, miRNAs are susceptible to interference by other components in the peripheral circulation, bringing into question the diagnostic value of circulating miRNAs. Exosomes secreted by most cell types contain proteins, mRNAs, and miRNAs that are closely associated with changes in cellular functions. Exosome miRNAs (ex-miRNAs) are highly stable and resistant to degradation. Therefore, these may serve as useful biomarkers for the early clinical diagnosis of dementia. Here, we review studies of ex-miRNAs that commonly cause clinical dementia and explore whether ex-miRNAs may be used as early diagnostic biomarkers of dementia.Keywords
This publication has 92 references indexed in Scilit:
- Altered Biogenesis and MicroRNA Content of Hippocampal Exosomes Following Experimental Status EpilepticusFrontiers in Neuroscience, 2020
- miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer’s PatientsFrontiers in Neuroscience, 2019
- Parkinson’s Disease–Mild Cognitive Impairment (PD-MCI): A Useful Summary of Update KnowledgeFrontiers in Aging Neuroscience, 2019
- Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related DiseasesCellular and Molecular Neurobiology, 2019
- Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementiasAnnals of Clinical and Translational Neurology, 2018
- MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson DiseaseFrontiers in Molecular Neuroscience, 2017
- Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's DiseaseCurrent Alzheimer Research, 2017
- MicroRNA biomarkers of Parkinson’s disease in serum exosome-like microvesiclesNeuroscience Letters, 2017
- A Panel of Oxidative Stress Markers in Parkinson's DiseaseClinical Laboratory, 2016
- Interleukin-10 Production in Response to Amyloid-β Differs between Slow and Fast Decliners in Patients with Alzheimer’s DiseaseJournal of Alzheimer’s Disease, 2015